Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PCVX

Vaxcyte Inc

Dec 11 • 04:00PM ET

91.05

Dollar change +0.62
Percentage change 0.69	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX AZN JNJ GSK ALNY NVCR VNDA

| Held by: VTI IWM VB VXF VBK IWO IBB XBI VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.68	Insider Own	3.47%	Shs Outstand	124.43M	Perf Week	-2.14%
Market Cap	11.35B	Forward P/E	-	EPS next Y	-4.69	Insider Trans	-7.01%	Shs Float	120.31M	Perf Month	-12.15%
Income	-507.65M	PEG	-	EPS next Q	-1.12	Inst Own	107.36%	Short Float	9.17%	Perf Quarter	-20.22%
Sales	0.00M	P/S	-	EPS this Y	5.15%	Inst Trans	13.64%	Short Ratio	10.48	Perf Half Y	23.16%
Book/sh	27.47	P/B	3.31	EPS next Y	-19.33%	ROA	-20.08%	Short Interest	11.03M	Perf Year	57.44%
Cash/sh	17.49	P/C	5.20	EPS next 5Y	-	ROE	-21.06%	52W Range	53.83 - 121.06	Perf YTD	44.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.98%	ROI	-14.77%	52W High	-24.79%	Beta	0.94
Dividend TTM	-	Quick Ratio	17.88	Sales past 5Y	0.00%	Gross Margin	-	52W Low	69.14%	ATR (14)	3.85
Dividend Ex-Date	-	Current Ratio	17.88	EPS Y/Y TTM	-40.18%	Oper. Margin	-	RSI (14)	42.31	Volatility	3.76% 4.37%
Employees	254	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	151.75
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	8.53%	Payout	-	Rel Volume	0.50	Prev Close	90.43
Sales Surprise	-	EPS Surprise	24.60%	Sales Q/Q	-	Earnings	Nov 05 AMC	Avg Volume	1.05M	Price	91.05
SMA20	0.28%	SMA50	-11.13%	SMA200	8.15%	Trades		Volume	528,112	Change	0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Dec-09-24 07:57AM	What Makes Vaxcyte (PCVX) An Investment Bet? (Insider Monkey)
Dec-04-24 10:03AM	Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants (Clinical Trials Arena)
Dec-03-24 08:00AM	Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Nov-27-24 09:29AM	Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug (Insider Monkey)
Nov-12-24 07:30AM	Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs (GlobeNewswire)
12:09AM	Loading…
Nov-06-24 12:09AM	Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight (GuruFocus.com)
Nov-05-24 04:01PM	Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-24 09:13AM	Should You Consider Investing in Vaxcyte (PCVX)? (Insider Monkey)
Sep-14-24 07:47PM	Vaxcyte, Inc. (PCVX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-11-24 04:05PM	Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 04:05PM	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Obesity drug startup raises $67M; Vors shielded transplant shows promise (BioPharma Dive)
Sep-04-24 11:58PM	Vaxcyte Announces Pricing of $1.3 Billion Public Offering (GlobeNewswire)
Sep-03-24 06:06PM	Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales (Bloomberg) +36.39%
04:09PM	Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market (Investor's Business Daily)
04:01PM	Loading…
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
01:22PM	Heard on the Street: Pfizer Better Watch Out for This Biotech (The Wall Street Journal)
11:43AM	Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why. (Barrons.com)
10:48AM	Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data. (Barrons.com)
09:40AM	Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher (Benzinga)
09:07AM	Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market (Investor's Business Daily)
08:10AM	Vaxcytes best-case data for pneumococcal vaccine boost shares (BioPharma Dive)
07:07AM	Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Sep-02-24 06:40PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Aug-06-24 04:05PM	Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 07:02PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Jul-31-24 09:55AM	Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? (Zacks)
Jul-29-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice (Zacks)
Jul-02-24 07:01PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
08:30AM	Vaxcyte Appoints John Furey to Board of Directors (GlobeNewswire)
12:32PM	Loading…
May-10-24 12:32PM	Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview (GuruFocus.com)
May-08-24 10:55PM	PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-04-24 02:31AM	Insider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Apr-22-24 04:46PM	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing (MT Newswires)
Apr-02-24 04:05PM	Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com)
Mar-20-24 07:01PM	Insider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-04-24 08:30AM	Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants (GlobeNewswire)
Feb-28-24 12:08PM	Q4 2023 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents) -7.33%
12:00PM	Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know (Zacks)
09:57AM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-24 08:32AM	Why Vaxcyte (PCVX) Might Surprise This Earnings Season (Zacks)
Feb-25-24 11:05AM	5 Best Russell 2000 Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-22-24 11:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Feb-15-24 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (GlobeNewswire)
Feb-02-24 11:12PM	Director Heath Lukatch Sells 5,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
06:39PM	Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-01-24 11:02PM	Director Heath Lukatch Sells 4,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +5.75%
04:05PM	Vaxcyte to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-30-24 11:37PM	Vaxcyte Announces Pricing of $750 Million Public Offering (GlobeNewswire) +6.04%
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-29-24 08:30AM	Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older (GlobeNewswire) +6.52%
Jan-19-24 08:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Jan-16-24 04:01PM	Vaxcyte Appoints Whitney Jones as Chief People Officer (GlobeNewswire)
Jan-04-24 04:01PM	Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise (GlobeNewswire) -7.07%
Dec-21-23 05:01PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Dec-04-23 06:35PM	VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate (GlobeNewswire)
Nov-28-23 08:30AM	Vaxcyte Appoints Jacks Lee to Board of Directors (GlobeNewswire)
Nov-27-23 04:00PM	Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates (GlobeNewswire)
Nov-23-23 11:04AM	Insider Sell Alert: Vaxcyte Inc's President and CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Nov-09-23 08:30AM	Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire) -5.06%
Nov-06-23 05:19PM	Vaxcyte Inc (PCVX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:03PM	Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 11:54PM	Insider Sell: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +6.17%
Oct-31-23 04:05PM	Vaxcyte to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-20-23 09:55PM	Insider Sell: Andrew Guggenhime Sells 8,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Oct-19-23 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Oct-16-23 08:00AM	Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs) (GlobeNewswire)
Oct-04-23 11:00PM	Insider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Sep-19-23 04:05PM	Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-11-23 08:21AM	Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up (Zacks)
Sep-08-23 04:44PM	Peninsula biotech grabs more space as it plans to take 2nd pneumonia vaccine into clinic (American City Business Journals)
Aug-08-23 04:03PM	Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-11-23 08:30AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jul-01-23 09:05AM	Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-13-23 09:30AM	5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good (Zacks)
Jun-01-23 04:05PM	Vaxcyte to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-29-23 09:55AM	Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet (Zacks)
May-12-23 09:55AM	Wall Street Analysts Believe Vaxcyte, Inc. (PCVX) Could Rally 26.15%: Here's is How to Trade (Zacks)
May-08-23 04:03PM	Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-03-23 04:05PM	Vaxcyte to Present at the BofA Securities 2023 Health Care Conference (GlobeNewswire) +5.21%
Apr-21-23 05:25PM	Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-19-23 11:36AM	Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates (Zacks)
12:26AM	Vaxcyte Announces Pricing of $500 Million Public Offering (GlobeNewswire)
Apr-18-23 12:56PM	Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data (Zacks)
Apr-17-23 04:05PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +16.00%
06:30AM	Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies (GlobeNewswire)
Apr-16-23 05:00PM	Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies (GlobeNewswire)
Mar-30-23 08:30AM	Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Mar-12-23 11:55PM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-27-23 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-23 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Feb-16-23 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (GlobeNewswire)
Feb-07-23 04:05PM	Vaxcyte to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-22-23 07:39AM	We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely (Simply Wall St.)
Jan-05-23 08:30AM	Vaxcytes VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Jan-03-23 12:34PM	This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst (Benzinga)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Dec 09 '24	Sale	92.25	2,366	218,253	136,215	Dec 10 04:10 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Dec 05 '24	Option Exercise	21.41	5,000	107,050	33,697	Dec 09 06:28 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Dec 05 '24	Sale	91.49	5,000	457,434	28,697	Dec 09 06:28 PM
PICKERING GRANT	Officer	Dec 09 '24	Proposed Sale	93.68	2,366	221,647		Dec 09 04:07 PM
Eydelman Mikhail	Officer	Dec 05 '24	Proposed Sale	92.75	5,000	463,750		Dec 05 04:04 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Dec 02 '24	Sale	92.45	15,000	1,386,794	450,301	Dec 03 07:15 PM
Wassil Jim	CHIEF OPERATING OFFICER	Dec 02 '24	Option Exercise	2.42	8,000	19,360	213,695	Dec 03 07:13 PM
Wassil Jim	CHIEF OPERATING OFFICER	Dec 02 '24	Sale	92.49	8,000	739,885	205,695	Dec 03 07:13 PM
Wassil Jim	Officer	Dec 02 '24	Proposed Sale	94.01	8,000	752,080		Dec 02 04:07 PM
PICKERING GRANT	Officer	Dec 02 '24	Proposed Sale	94.01	15,000	1,410,150		Dec 02 04:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Nov 18 '24	Option Exercise	5.35	8,000	42,800	117,491	Nov 19 04:43 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Nov 18 '24	Sale	85.81	8,000	686,518	109,491	Nov 19 04:43 PM
GUGGENHIME ANDREW	Officer	Nov 18 '24	Proposed Sale	86.50	8,000	692,000		Nov 18 04:02 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Nov 07 '24	Option Exercise	3.71	30,792	114,308	466,011	Nov 08 08:46 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Nov 07 '24	Sale	103.89	2,366	245,796	137,398	Nov 08 08:46 PM
PICKERING GRANT	Officer	Nov 07 '24	Proposed Sale	104.08	2,366	246,253		Nov 07 04:13 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Nov 05 '24	Option Exercise	21.41	5,000	107,050	33,623	Nov 06 04:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Nov 05 '24	Sale	106.36	5,000	531,803	28,623	Nov 06 04:15 PM
Eydelman Mikhail	Officer	Nov 05 '24	Proposed Sale	105.18	5,000	525,900		Nov 05 04:08 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Nov 01 '24	Sale	106.82	15,000	1,602,252	435,219	Nov 04 06:46 PM
Wassil Jim	CHIEF OPERATING OFFICER	Nov 01 '24	Option Exercise	2.42	8,000	19,360	213,695	Nov 04 06:45 PM
Wassil Jim	CHIEF OPERATING OFFICER	Nov 01 '24	Sale	106.80	8,000	854,423	205,695	Nov 04 06:45 PM
PICKERING GRANT	Officer	Nov 01 '24	Proposed Sale	106.76	15,000	1,601,400		Nov 01 04:04 PM
Wassil Jim	Officer	Nov 01 '24	Proposed Sale	106.76	8,000	854,080		Nov 01 04:02 PM
Wassil Jim	CHIEF OPERATING OFFICER	Oct 28 '24	Option Exercise	16.04	5,049	80,981	205,695	Oct 29 07:41 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Oct 25 '24	Option Exercise	20.93	19,108	399,930	109,491	Oct 28 05:11 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Oct 18 '24	Option Exercise	5.35	42,000	224,700	132,383	Oct 22 04:11 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Oct 18 '24	Sale	115.39	42,000	4,846,508	90,383	Oct 22 04:11 PM
GUGGENHIME ANDREW	Officer	Oct 18 '24	Proposed Sale	115.88	42,000	4,866,960		Oct 18 04:02 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Oct 07 '24	Sale	109.21	7,098	775,154	138,581	Oct 08 08:32 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Oct 07 '24	Option Exercise	21.41	5,000	107,050	33,623	Oct 08 08:29 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Oct 07 '24	Sale	109.27	5,000	546,353	28,623	Oct 08 08:29 PM
PICKERING GRANT	Officer	Oct 07 '24	Proposed Sale	111.12	7,098	788,730		Oct 07 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Oct 01 '24	Option Exercise	5.35	40,000	214,000	470,219	Oct 03 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Oct 01 '24	Sale	114.25	55,000	6,283,861	450,219	Oct 03 04:17 PM
Wassil Jim	CHIEF OPERATING OFFICER	Oct 01 '24	Option Exercise	2.42	8,000	19,360	208,646	Oct 03 04:16 PM
Wassil Jim	CHIEF OPERATING OFFICER	Oct 01 '24	Sale	114.24	8,000	913,917	200,646	Oct 03 04:16 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Oct 01 '24	Option Exercise	21.41	5,500	117,755	34,123	Oct 03 04:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Oct 01 '24	Sale	114.24	5,500	628,295	28,623	Oct 03 04:15 PM
PICKERING GRANT	Officer	Oct 01 '24	Proposed Sale	114.55	55,000	6,300,250		Oct 01 04:04 PM
Eydelman Mikhail	Officer	Oct 01 '24	Proposed Sale	114.55	5,500	630,025		Oct 01 04:04 PM
Wassil Jim	Officer	Oct 01 '24	Proposed Sale	114.55	8,000	916,400		Oct 01 04:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Sep 18 '24	Option Exercise	5.35	8,000	42,800	98,383	Sep 19 05:48 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Sep 18 '24	Sale	115.94	8,000	927,551	90,383	Sep 19 05:48 PM
Loxam Teri	Director	Sep 17 '24	Option Exercise	22.70	6,250	141,875	13,425	Sep 18 04:24 PM
Loxam Teri	Director	Sep 17 '24	Sale	116.28	6,250	726,731	7,175	Sep 18 04:24 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 16 '24	Option Exercise	2.42	10,000	24,200	211,958	Sep 18 04:23 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 16 '24	Sale	115.96	10,000	1,159,635	200,646	Sep 18 04:23 PM
GUGGENHIME ANDREW	Officer	Sep 18 '24	Proposed Sale	116.75	8,000	934,000		Sep 18 04:11 PM
Loxam Teri	Director	Sep 17 '24	Proposed Sale	113.93	6,250	712,062		Sep 17 04:11 PM
Wassil Jim	Officer	Sep 16 '24	Proposed Sale	115.90	10,000	1,159,000		Sep 16 04:17 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 03 '24	Option Exercise	2.42	10,000	24,200	217,503	Sep 05 05:19 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 03 '24	Sale	111.93	10,000	1,119,252	207,503	Sep 05 05:19 PM
Cowan Elvia	SVP, FINANCE	Sep 03 '24	Option Exercise	25.92	5,000	129,600	17,723	Sep 05 05:15 PM
Cowan Elvia	SVP, FINANCE	Sep 03 '24	Sale	107.67	5,000	538,350	12,723	Sep 05 05:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Sep 03 '24	Option Exercise	21.41	1,667	35,690	32,493	Sep 05 05:13 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Sep 03 '24	Sale	112.11	1,667	186,880	30,826	Sep 05 05:13 PM
Cowan Elvia	Officer	Sep 03 '24	Proposed Sale	107.67	5,000	538,350		Sep 03 04:08 PM
Wassil Jim	Officer	Sep 03 '24	Proposed Sale	107.67	10,000	1,076,700		Sep 03 04:07 PM
Eydelman Mikhail	Officer	Sep 03 '24	Proposed Sale	107.67	1,667	179,485		Sep 03 04:04 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Option Exercise	2.03	15,000	30,450	493,888	Aug 26 04:58 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Sale	78.98	15,000	1,184,767	478,888	Aug 26 04:58 PM
PICKERING GRANT	Officer	Aug 23 '24	Proposed Sale	78.89	15,000	1,183,350		Aug 23 04:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 19 '24	Option Exercise	5.35	8,000	42,800	104,720	Aug 20 04:49 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 19 '24	Sale	78.58	8,000	628,650	96,720	Aug 20 04:49 PM
GUGGENHIME ANDREW	Officer	Aug 19 '24	Proposed Sale	78.91	8,000	631,280		Aug 19 04:05 PM
Wassil Jim	CHIEF OPERATING OFFICER	Aug 01 '24	Sale	78.84	3,000	236,527	207,503	Aug 05 04:10 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 01 '24	Sale	78.79	2,616	206,122	142,130	Aug 05 04:08 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Aug 01 '24	Option Exercise	21.41	1,667	35,690	32,493	Aug 05 04:06 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Aug 01 '24	Sale	78.85	1,667	131,449	30,826	Aug 05 04:06 PM
PICKERING GRANT	Officer	Aug 01 '24	Proposed Sale	78.80	2,616	206,141		Aug 01 04:04 PM
Wassil Jim	Officer	Aug 01 '24	Proposed Sale	78.80	3,000	236,400		Aug 01 04:02 PM
Eydelman Mikhail	Officer	Aug 01 '24	Proposed Sale	78.80	1,667	131,360		Aug 01 04:01 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Option Exercise	2.03	15,000	30,450	493,888	Jul 24 05:44 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Sale	84.26	15,000	1,263,912	478,888	Jul 24 05:44 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jul 18 '24	Option Exercise	5.35	8,000	42,800	104,720	Jul 22 04:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jul 18 '24	Sale	81.17	8,000	649,325	96,720	Jul 22 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 16 '24	Option Exercise	25.92	5,000	129,600	17,723	Jul 17 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 16 '24	Sale	85.00	5,000	425,000	12,723	Jul 17 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 08 '24	Option Exercise	25.92	5,000	129,600	17,723	Jul 09 05:15 PM
Cowan Elvia	SVP, FINANCE	Jul 08 '24	Sale	80.00	5,000	400,000	12,723	Jul 09 05:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jul 01 '24	Option Exercise	21.41	1,667	35,690	32,493	Jul 02 04:17 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jul 01 '24	Sale	76.37	1,667	127,304	30,826	Jul 02 04:17 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jul 01 '24	Sale	76.34	3,000	229,013	210,503	Jul 02 04:16 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 01 '24	Sale	76.33	2,616	199,690	143,438	Jul 02 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 24 '24	Option Exercise	2.03	15,000	30,450	493,888	Jun 25 04:43 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 24 '24	Sale	75.64	15,000	1,134,579	478,888	Jun 25 04:43 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '24	Option Exercise	5.35	8,000	42,800	104,720	Jun 20 08:30 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '24	Sale	71.92	8,000	575,375	96,720	Jun 20 08:30 PM
Gilbert Halley E	Director	Jun 03 '24	Option Exercise	5.35	18,200	97,370	23,825	Jun 05 04:59 PM
Gilbert Halley E	Director	Jun 03 '24	Sale	73.00	18,200	1,328,600	5,625	Jun 05 04:59 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jun 03 '24	Option Exercise	21.41	1,667	35,690	32,828	Jun 05 04:58 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jun 03 '24	Sale	72.06	1,667	120,127	31,161	Jun 05 04:58 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jun 03 '24	Sale	71.99	3,000	215,961	213,503	Jun 05 04:57 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 03 '24	Sale	72.06	2,616	188,512	144,746	Jun 05 04:56 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 23 '24	Option Exercise	2.03	15,000	30,450	492,847	May 28 04:22 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 23 '24	Sale	69.43	15,000	1,041,408	477,847	May 28 04:22 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	May 20 '24	Option Exercise	5.35	8,000	42,800	103,679	May 22 05:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	May 20 '24	Sale	74.99	8,000	599,909	95,679	May 22 05:03 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	May 01 '24	Option Exercise	21.41	1,667	35,690	32,264	May 03 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCVX

Vaxcyte Inc

Upgrade your FINVIZ experience